Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of ParkinsonD́s disease

Neurobiology of Disease

Volumn 62, Issue , 2014, Pages 416-425

  González Aparicio, Ramiro ^a,b   Moratalla, Rosario ^a,b  

^a INSTITUTO CAJAL   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Cannabinoids; Capsaicin; Endocannabinoids; OEA; PPAR receptors

Indexed keywords

ENDOCANNABINOID; HISTONE H3; LEVODOPA; N OLEOYLETHANOLAMINE; TRANSCRIPTION FACTOR FOSB; VANILLOID RECEPTOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DYSKINESIA; HISTONE ACETYLATION; MALE; MOTOR ACTIVITY; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CANNABINOIDS; CAPSAICIN; ENDOCANNABINOIDS; OEA; PPARΑ RECEPTORS;

ANIMALS; ANTI-DYSKINESIA AGENTS; ANTIPARKINSON AGENTS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DYSKINESIA, DRUG-INDUCED; LEVODOPA; MALE; MICE; MICE, INBRED C57BL; MOTOR ACTIVITY; OLEIC ACIDS; OXIDOPAMINE; PARKINSON DISEASE; TRPV CATION CHANNELS;

EID: 84887514200     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2013.10.008     Document Type: Article

References (96)

1. Almasi R., Szoke E., Bölcskei K., Varga A., Riedl Z., Sandor Z., et al. Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci. 2008, 82:644-651.
2. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
3. Ares-Santos S., Granado N., Oliva I., O'Shea E., Martin E.D., Colado M.I., et al. Dopamine D1 receptor deletion strongly reduces neurotoxic effects of methamphetamine. Neurobiol. Dis. 2012, 45:810-820.
4. Aubert I., Guigoni C., Håkansson K., Li Q., Dovero S., Barthe N., et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann. Neurol. 2005, 57:17-26.
5. Ben-Shabat S., Fride E., Sheskin T., Tamiri T., Rhee M.H., Vogel Z., et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur. J. Pharmacol. 1998, 353:23-31.
6. Berthet A., Porras G., Doudnikoff E., Stark H., Cador M., Bezard E., et al. Pharmacological analysis demonstrates dramatic alteration of D1 dopamine receptor neuronal distribution in the rat analog of L-DOPA-induced dyskinesia. J. Neurosci. 2009, 29:4829-4835.
7. Bido S., Marti M., Morari M. Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels. J. Neurochem. 2011, 118:1043-1055.
8. Bisogno T., Berrendero F., Ambrosino G., Cebeira M., Ramos J.A., Fernández-Ruiz J., et al. Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function. Biochem. Biophys. Res. Commun. 1999, 256:377-380.
9. Breese G.R., Traylor T.D. Depletion of brain noradrenaline and dopamine by 6-hydroxydopamine. Br. J. Pharmacol. 1971, 42:88-99.
10. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 2005, 20:919-931.
11. Cao X., Liang L., Hadcock J.R., Iredale P.A., Griffith D.A., Menniti F.S., et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 2007, 323:318-326.
12. Carroll C.B., Bain P.G., Teare L., Liu X., Joint C., Wroath B.A., et al. Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 2004, 63:1245-1250.
13. Carta M., Carlsson T., Kirik D., Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007, 130:1819-1833.
14. Cenci M.A., Konradi C. Maladaptative striatal plasticity in L-DOPA-induced dyskinesia. Prog. Brain Res. 2010, 183:209-233.
15. Cenci M.A., Lundblad M. Post- versus presynaptic plasticity in L-DOPA induced dyskinesia. J. Neurochem. 2006, 99:381-392.
16. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Curr Protoc Neurosci 2007, [Chapter 9 Unit 9.25]. http://dx.doi.org/10.1002/0471142301.ns0925s41.
17. Centonze D., Grande C., Saulle E., Martín A.B., Gubellini P., Pavón N., et al. Distinct roles of D1 and D5 dopamine receptors in motor activity and striatal synaptic plasticity. J. Neurosci. 2003, 23:8506-8512.
18. Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139:1405-1415.
19. Darmopil S., Muñetón-Gómez V.C., de Ceballos M.L., Bernson M., Moratalla R. Tyrosine hydroxylase cells appearing in the mouse striatum after dopamine denervation are likely to be projection neurones regulated by L-DOPA. Eur. J. Neurosci. 2008, 27:580-592.
20. Darmopil S., Martín A.B., de Diego I.R., Ares S., Moratalla R. Genetic inactivation of dopamine D1 but not D2 receptors inhibits L-DOPA-induced dyskinesia and histone activation. Biol. Psychiatry 2009, 66:603-613.
21. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 2004, 1007:152-159.
22. Demirbilek S., Ersoy M.O., Demirbilek S., Karaman A., Gurbuz N., Bayraktar N., et al. Small-dose capsaicin reduces systemic inflammatory responses in septic rats. Anesth. Analg. 2004, 99:1501-1507.
23. Devane W.A., Dysarz F.A., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol. 1988, 34:605-613.
24. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 1992, 258:1946-1949.
25. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol. 2008, 160:1-24.
26. Di Marzo V., Melck D., Bisogno T., De Petrocellis L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. 1998, 21:521-528.
27. Dupre K.B., Ostock C.Y., Eskow Jaunarajs K.L., Button T., Savage L.M., Wolf W., et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp. Neurol. 2011, 229:288-299.
28. Egertova M., Cravatt B.F., Elphick M.R. Comparative analysis of fatty acid amide hydrolase and CB1 cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 2003, 119:481-496.
29. Espadas I., Darmopil S., Vergaño-Vera E., Ortiz O., Oliva I., Vicario-Abejón C., et al. L-DOPA-induced increase in TH-immunoreactive striatal neurons in parkinsonian mice: insights into regulation and function. Neurobiol. Dis. 2012, 48:271-281.
30. Fernández-Espejo E., Ramiro-Fuentes S., Rodríguez de Fonseca F. The absence of a functional peroxisome proliferator activated receptor-alpha gene in mice enhances motor sensitizing effects of morphine, but not cocaine. Neuroscience 2009, 164:667-675.
31. Fernández-Ruiz J. The endocannabinoid system as a target for the treatment of motor dysfunction. Br. J. Pharmacol. 2009, 156:1029-1040.
32. Ferrer B., Asbrock N., Kathuria S., Piomelli D., Giuffrida A. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias. Eur. J. Neurosci. 2003, 18:1607-1614.
33. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Mov. Disord. 2002, 17:1180-1187.
34. Fu J., Gaetani S., Oveisi F., Lo Verme J., Serrano A., Rodríguez De Fonseca F., et al. Oleoylethanolamide regulates feeding and body weight through activation of the nuclear receptor PPAR-alpha. Nature 2003, 425:90-93.
35. Galán-Rodríguez B., Suárez J., González-Aparicio R., Bermúdez-Silva F.J., Maldonado R., Robledo P., et al. Oleoylethanolamide exerts partial and dose-dependent neuroprotection of substantia nigra dopamine neurons. Neuropharmacology 2009, 56:653-664.
36. García M.C., Adler-Graschinsky E., Celuch S.M. Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide. Eur. J. Pharmacol. 2009, 610:75-80.
37. González-Aparicio R., Flores J.A., Fernández-Espejo E. Antiparkinsonian trophic action of glial cell line-derived neurotrophic factor and transforming growth factor β1 is enhanced after co-infusion in rats. Exp. Neurol. 2010, 226:136-147.
38. González-Aparicio R., Flores J.A., Tasset I., Túnez I., Fernández-Espejo E. Mice lacking the peroxisome proliferator-activated receptor alpha gene present reduced number of dopamine neurons in the substantia nigra without altering motor behaviour or dopamine neuron decline over life. Neuroscience 2011, 186:161-169.
39. Granado N., Escobedo I., O'Shea E., Colado I., Moratalla R. Early loss of dopaminergic terminals in striosomes after MDMA administration to mice. Synapse 2008, 62:80-84.
40. Granado N., O'Shea E., Bove J., Vila M., Colado I., Moratalla R. Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J. Neurochem. 2008, 107:1102-1112.
41. Granado N., Ortiz O., Suárez L.M., Martín E.D., Ceña V., Solís J.M., et al. D1 but not D5 dopamine receptors are critical for LTP, spatial learning, and LTP-induced arc and zif268 expression in the hippocampus. Cereb. Cortex 2008, 18:1-12.
42. Granado N., Ares-Santos S., Oliva I., O'Shea E., Martin E.D., Colado M.I., et al. Dopamine D2-receptor knockout mice are protected against dopaminergic neurotoxicity induced by methamphetamine or MDMA. Neurobiol. Dis. 2011, 42:391-403.
43. Grande C., Zhu H., Martin A.B., Lee M., Ortiz O., Hiroi N., et al. Chronic treatment with atypical neuroleptics induces striosomal FosB/DeltaFosB expression in rats. Biol. Psychiatry 2004, 55:457-463.
44. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., et al. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 2002, 22:6900-6907.
45. Guzmán M., Sánchez C., Galve-Roperh I. Control of the cell survival/death decision by cannabinoids. J. Mol. Med. 2001, 78:613-625.
46. Hermann H., De Petrocellis L., Bisogno T., Schiano Moriello A., Lutz B., Di Marzo V. Dual effect of cannabinoid CB1 receptor stimulation on a vanilloid VR1 receptor-mediated response. Cell. Mol. Life Sci. 2003, 60:607-616.
47. Ho W.S., Barret D.A., Randall M.D. "Entourage" effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 2008, 155:837-846.
48. Hodgson R.A., Bertorelli R., Varty G.B., Lachowicz J.E., Forlani A., Fredduzzi S., et al. Characterization of the potent and highly selective A2A receptor antagonists preladenant and SCH 412348 [7-[2-[4-2,4-difluorophenyl]-1-piperazinyl]ethyl]-2-(2-furanyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine in rodent models of movement disorders and depression. J. Pharmacol. Exp. Ther. 2009, 330:294-303.
49. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004, 62:S47-S55.
50. Julian M.D., Martín A.B., Cuéllar B., Rodríguez de Fonseca F., Navarro M., Moratalla R., et al. Neuroanatomical relationship between type 1 cannabinoid receptors and dopaminergic systems in the rat basal ganglia. Neuroscience 2003, 119:309-318.
51. Kelsey J.E., Harris O., Cassin J. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. Behav. Brain Res. 2009, 203:304-307.
52. Kirik D., Rosenblad C., Björklund A., Mandel R.J. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J. Neurosci. 2000, 20:4686-4700.
53. Labar G., Michaux C. Fatty acid amide hydrolase: from characterization to therapeutics. Chem. Biodivers. 2007, 4:1882-1902.
54. Lastres-Becker I., Hansen H.H., Berrendero F., de Miguel R., Pérez-Rosado A., Manzanares J., et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002, 44:23-35.
55. Lastres-Becker I., de Miguel R., De Petrocellis L., Makriyannis A., Di Marzo V., Fernández-Ruiz J. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesias in a rat model of Huntington's disease. J. Neurochem. 2003, 84:1097-1109.
56. Lee J., Di Marzo V., Brotchie J.M. A role for vanilloid receptor 1 (TRPV1) and endocannabinoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 2006, 51:557-565.
57. Lee T.H., Lee J.G., Yon J.M., Oh K.W., Baek I.J., Nahm S.S., et al. Capsaicin prevents kainic acid-induced epileptogenesis in mice. Neurochem. Int. 2011, 58:634-640.
58. Lo Verme J., Fu J., Astarita G., La Rana G., Russo R., Calignano A., et al. The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 2005, 67:15-19.
59. Mackie K. Cannabinoid receptors as therapeutic targets. Annu. Rev. Pharmacol. Toxicol. 2006, 46:101-122.
60. Mailleux P., Vanderhaeghen J.J. Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry. Neuroscience 1992, 48:655-668.
61. Marinelli S., Di Marzo V., Berretta N., Matias I., Maccarrone M., Bernardi G., et al. Presynaptic facilitation of glutamatergic synapses to dopaminergic neurons of the rat substantia nigra by endogenous stimulation of vanilloid receptors. J. Neurosci. 2003, 23:3136-3144.
62. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 1994, 17:S32-S44.
63. Martín A.B., Fernández-Espejo E., Ferrer B., Gorriti M.A., Bilbao A., Navarro M., et al. Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. Neuropsychopharmacology 2008, 33:1667-1679.
64. Martínez A., Macheda T., Morgese M.G., Trabace L., Giuffrida A. The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats. Neurosci. Res. 2012, 72:236-242.
65. Mesnage V., Houeto J.L., Bonnet A.M., Clavier I., Arnulf I., Cattelin F., et al. Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease. Clin. Neuropharmacol. 2004, 27:108-110.
66. Morgese M.G., Cassano T., Cuomo V., Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 2007, 208:110-119.
67. Morgese M.G., Cassano T., Gaetani S., Macheda T., Laconca L., Dipasquale P., et al. Neurochemical changes in the striatum of dyskinetic rats after administration of the cannabinoid agonist WIN55,212-2. Neurochem. Int. 2009, 54:56-64.
68. Munro S., Thomas K., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
69. Murer G., Moratalla R. Striatal signaling in L-DOPA-induced dyskinesia: common mechanisms with drug abuse and long term memory involving D1 dopamine receptor stimulation. Front. Neuroanat. 2011, 5:51.
70. Pavón N., Martín A.B., Mendialdua A., Moratalla R. ERK phosphorylation and FosB expression are associated with L-DOPA-induced dyskinesia in hemiparkinsonian mice. Biol. Psychiatry 2006, 59:64-74.
71. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2004, San Diego, CA, Academic Press. 2nd ed.
72. Piomelli D., Beltramo M., Giuffrida A., Stella N. Endogenous cannabinoid signaling. Neurobiol. Dis. 1998, 5:462-473.
73. Porras G., Berthet A., Dehay B., Li Q., Ladepeche L., Normand E., et al. PSD-95 expression controls L-DOPA dyskinesia through dopamine D1 receptor trafficking. J. Clin. Invest. 2012, 122:3977-3989.
74. Reyes-Cabello C., Alen F., Gómez R., Serrano A., Rivera P., Orio L., et al. Effects of the anandamide uptake blocker AM404 on food intake depend on feeding status and route of administration. Pharmacol. Biochem. Behav. 2012, 101:1-7.
75. Rivera A., Alberti I., Martín A.B., Narváez J.A., de la Calle A., Moratalla R. Molecular phenotype of rat striatal neurons expressing the dopamine D5 receptor subtype. Eur. J. Neurosci. 2002, 16:2049-2058.
76. Rodríguez de Fonseca F., Navarro M., Gómez R., Escuredo L., Nava F., Fu J., et al. An anorexic lipid mediator regulated by feeding. Nature 2001, 414:209-212.
77. Santini E., Valjent E., Usiello A., Carta M., Borqkvist A., Girault J.A., et al. Critical involvement of cAMP/DARPP-32 and extracelular signal-regulated protein kinase signaling in L-DOPA-induced dyskinesia. J. Neurosci. 2007, 27:6995-7005.
78. Santini E., Alcacer C., Cacciatore S., Heiman M., Herve D., Greengard P., et al. L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice. J. Neurochem. 2009, 108:621-633.
79. Sarne Y., Keren O. Are cannabinoid drugs neurotoxic or neuroprotective?. Med. Hypotheses 2004, 63:187-192.
80. Sauer H., Oertel W.H. Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: a combined retrograde tracing and inmunocytochemical study in the rat. Neuroscience 1994, 59:401-415.
81. Segovia G., Mora F., Crossman A.R., Brotchie J.M. Effect of CB1 cannabinoid receptor modulating compounds on the hyperkinesia induced by high-dose levodopa in the reserpine-treated rat model of Parkinson's disease. Mov. Disord. 2003, 18:138-149.
82. Sieradzan K.A., Fox S.H., Hill M., Dick J.P.R., Crossman A.R., Brotchie J.M. Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study. Neurology 2001, 57:2108-2111.
83. Smart D., Gunthorpe M.J., Jerman J.C., Nasir S., Gray J., Muir A.I., et al. The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. 2000, 129:227-230.
84. Smart D., Jonsson K., Vandevoorde S., Lambert D.M., Fowler C.F. "Entourage" effects of N-acyl ethanolamines at human vanilloid receptors. Comparison of effects upon anandamide-induced vanilloid receptor activation and upon anandamide metabolism. Br. J. Pharmacol. 2002, 136:452-458.
85. Solbrig M.V., Adrian R., Baratta J., Piomelli D., Giuffrida A. A role for endocannabinoids in viral-induced dyskinetic and convulsive phenomena. Exp. Neurol. 2005, 194:355-362.
86. Suárez J., Ortiz O., Puente N., Bermúdez-Silva F.J., Blanco E., Fernández-Llebrez P., et al. Distribution of diacylglycerol lipase alpha, an endocannabinoid synthesizing enzyme, in the rat forebrain. Neuroscience 2011, 192:112-131.
87. Suárez L.M., Solís O., Caramés J.M., Taravini I.R., Solís J.M., Murer M.G., et al. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol. Psychiatry 2013, (http://dx.doi.org/10.1016/j.biopsych.2013.05.006, in press).
88. Sun Y., Bennett A. Cannabinoids: a new group of agonists of PPARs. PPAR Res. 2007, 2007:23513-23519.
89. Szallasi A., Di Marzo V. New perspectives on enigmatic vanilloid receptors. Trends Neurosci. 2000, 23:491-497.
90. Thabuis C., Tissot-Favre D., Bezelgues J.B., Martín J.C., Cruz-Hernández C., Dionisi F., et al. Biological functions and metabolism of oleoylethanolamide. Lipids 2008, 43:887-894.
91. van der Stelt M., Di Marzo V. Endovanilloids. Putative endogenous ligands of transient receptor potential vanilloid 1 channels. Eur. J. Biochem. 2004, 271:1827-1834.
92. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. FASEB J. 2005, 19:1140-1142.
93. Walsh S., Gorman A.M., Finn D.P., Dowd E. The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats. Brain Res. 2010, 1363:40-48.
94. Wang X., Miyares R.L., Ahern G.P. Oleoylethanolamide excites vagal sensory neurones, induces visceral pain and reduces short-term food intake in mice via capsaicin receptor TRPV1. J. Physiol. 2005, 564:541-547.
95. Zeng B.Y., Dass B., Owen A., Rose S., Cannizzaro C., Tel B.C., et al. Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 1999, 276:71-74.
96. Zygmunt P.M., Petersson J., Andersson D.A., Chuang H., Sorgard M., Di Marzo V., et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999, 400:452-457.